Sino Biopharmaceutical Limited announced on Thursday that it had signed an exclusive strategic cooperation agreement with Sciwind Biosciences, a biotech company researching innovative treatments based in Hangzhou, Zhejiang province.

The deal will bring in a candidate drug of Sciwind Bioscience, which is expected to become China's first Class-1 innovative drug for nebulized treatment of pediatric respiratory syncytial virus, also known as RSV infections.

The drug candidate, known as CPX102, is the world's first nebulized treatment under development for RSV infection, targeting respiratory epithelial cells. It works quickly and is more effective in improving virological response time and enhancing viral clearance, the company claimed.

In addition, Sino Biopharmaceutical Limited also secured exclusive commercialization rights for CPX102 in 19 countries apart from China, including Brazil, Saudi Arabia, Thailand, and Singapore.